View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
ABGSC Investment Companies Research ... (+2)
  • ABGSC Investment Companies Research
  • Derek Laliberté
Maissa Keskes ... (+2)
  • Maissa Keskes
  • Stephane Houri

Nokia : Slightly better results, improving orders

>Q1 2024 results above expectations thanks to Nokia technologies and a better mix in Mobile, improving orders in Networks - Revenues totalled € 4.67bn, down 19% y-o-y at cc below the consensus at € 4.96m. Non-IFRS gross margin was 48.6%, above the consensus at 43.7% thanks to a strong contribution from Nokia Technologies which benefited from significant catch-up net sales in addition to a significant improvements in Mobile Networks partly due to the regional and produ...

Johanna Jourdain
  • Johanna Jourdain

Edenred : Q1 2024 beating estimates and reassuring on underlying growt...

>Q1 2024 revenue higher, with organic beat - Edenred has reported total Q1 2024 revenue of € 685m, 3% above forecasts (consensus at € 666m), i.e. a reported increase of 21.4%, of which +20.5% organic, +5.2% from M&A and -4.4% from the forex effect. Organic growth in operating revenues in Q1 was +16.9%, above the consensus at 14.2% (ODDO BHF 13.9%). All the regions are dynamic in organic terms, o/w Europe at +12.8% in Q1 (vs consensus +11.8%), including +7.9% in Fran...

SFA Engineering Corp: 1 director

A director at SFA Engineering Corp bought 1,300 shares at 24,350.000KRW and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

Sampath Bank Plc: 1 director

A director at Sampath Bank Plc sold 19,850,000 shares at 80.244LKR and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

Global Top E-Commerce Co Ltd: 1 director

A director at Global Top E-Commerce Co Ltd sold 2,538,800 shares at 2.170CNY and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
ABGSC IT Research ... (+3)
  • ABGSC IT Research
  • Daniel Thorsson
  • Simon Granath
Nicolas Thorez
  • Nicolas Thorez

Verimatrix : T1 24 en ligne. La transformation apparait de plus en plu...

>CA T1 2024 en ligne avec nos attentes à 14 M$, quasi-stable y/y (+1%) - Au T1, le CA de Verimatrix est ressorti à 14 M$, quasi-stable à +1% y-o-y, en ligne avec nos attentes (ODDO BHF 14.1 M$). Ce niveau d’activité reflète toujours des tendances contrastées avec un mix positif entre revenus récurrents (qui affichent une croissance meilleure qu’attendue) et revenus non récurrents (un peu plus faible qu’anticipé). Dans le détail, les revenus récurrents (60% des ventes)...

 PRESS RELEASE

EQS-News: BioLizard nomme Matthew Hall comme directeur du développeme...

EQS-News: BioLizard nv / Mot-clé(s) : Personnel BioLizard nomme Matthew Hall comme directeur du développement commercial 18.04.2024 / 09:00 CET/CEST BioLizard nomme Matthew Hall comme directeur du développement commercial Matthew G. Hall, PhD, apporte plus d'une décennie d'expérience en matière de relations stratégiques et de développement commercial dans les secteurs biotechnologique et pharmaceutique, avec un accent particulier sur les solutions basées sur l'IA. Cette nomination renforce la position de BioLizard sur le marché suisse, qui présente une importance stratégi...

 PRESS RELEASE

EQS-News: BioLizard ernennt Matthew Hall zum Director of Business Deve...

EQS-News: BioLizard nv / Schlagwort(e): Personalie BioLizard ernennt Matthew Hall zum Director of Business Development 18.04.2024 / 09:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. BioLizard ernennt Matthew Hall zum Director of Business Development  Dr. Matthew G. Hall bringt mehr als ein Jahrzehnt Erfahrung im strategischen BD mit Schwerpunkt auf dem Einsatz von KI-Technologien in der Biotech- und Pharmaindustrie mit. Mit dieser Personalie stärkt BioLizard seine Position auf dem Schweizer Markt, wo das Unternehmen kürzlich ein...

 PRESS RELEASE

EQS-News: Hauptversammlung 2024 von Redcare Pharmacy bestätigt alle Pu...

EQS-News: Redcare Pharmacy N.V. / Schlagwort(e): Hauptversammlung/Personalie Hauptversammlung 2024 von Redcare Pharmacy bestätigt alle Punkte der Tagesordnung. Dirk Brüse und Lode Fastré neue Mitglieder des Vorstands. 18.04.2024 / 09:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Hauptversammlung 2024 von Redcare Pharmacy bestätigt alle Punkte der Tagesordnung. Dirk Brüse und Lode Fastré neue Mitglieder des Vorstands. Sevenum, die Niederlande, 18. April 2024. Auf der gestrigen Hauptversammlung von Redcare Pharmacy stimmten die Sh...

 PRESS RELEASE

EQS-News: BioLizard Appoints Matthew Hall as Director of Business Deve...

EQS-News: BioLizard nv / Key word(s): Personnel BioLizard Appoints Matthew Hall as Director of Business Development 18.04.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. BioLizard Appoints Matthew Hall as Director of Business Development Matthew G. Hall, PhD, brings over a decade of experience in strategic partnerships and BD within the biotech and pharmaceutical sectors, with a particular focus on leveraging AI-driven solutions. Appointment strengthens BioLizards’ position in the strategically important Swiss market, where...

 PRESS RELEASE

EQS-News: Redcare Pharmacy's Annual General Meeting 2024 approved all ...

EQS-News: Redcare Pharmacy N.V. / Key word(s): AGM/EGM/Personnel Redcare Pharmacy's Annual General Meeting 2024 approved all agenda items. Dirk Brüse and Lode Fastré new members of the Managing Board. 18.04.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. Redcare Pharmacy's Annual General Meeting 2024 approved all agenda items. Dirk Brüse and Lode Fastré new members of the Managing Board. Sevenum, the Netherlands, 18 April, 2024. At Redcare Pharmacy’s Annual General Meeting held yesterday, shareholders voted with an absolute ma...

Oliver Metzger
  • Oliver Metzger

SARTORIUS AG : Some stabilisation, but sales and order intake below ex...

>Stabilisation of revenues, sequential improvement of order intake continues - Q1 revenues of € 820m (-9.3% y-o-y, -5%/-5% vs ODDO BHF/consensus) were impacted by a constant currency decline of 7.6% including 200bp coming from external growth. Sartorius continued to be impacted by destocking. Order intake of € 826m (-5.6% y-o-y) was -6%/-7% below expectations. We rate the development of the order book as still negative given the ongoing headwind. Adj. EBITDA of € 234m...

Oliver Metzger
  • Oliver Metzger

Sartorius Stedim Biotech : Q1 review -Some stabilisation, but sales an...

>Q1 with some stabilisation – sales and order intake weaker than expected - Q1 2024 revenues of € 667m (-8.1% y-o-y,-2%/-4% vs ODDO BHF/consensus) were impacted by an organic decline of 9.4%. The decline in constant currencies was at -6.7%. Sartorius Stedim Biotech was impacted by mixed dynamics across its portfolio and regions. Demand continued to normalise the consumables business with positive order momentum, which indicates further progress in destocking. Simultan...

Fatma Agnès Hamdani
  • Fatma Agnès Hamdani

Marie Brizard Wine & Spirits : 2023 results ahead of expectations. Uns...

>EBITDA up 12.2% at € 13.1m vs € 12.4m est. and positive net income of € 8.7m vs € 7.2m est. - MBWS’ results, reported yesterday evening, beat our expectations. EBITDA came in 12.2% higher at € 13.1m vs € 12.4m expected on already-reported sales of € 194.2m (+7.1% rep. and 7.2% in organic terms). The gross margin remains largely stable at € 70.7m, implying a drop in the gross margin of 270bp to 36.4%. Raw material and energy cost inflation and an unfavourable product ...

Emna Ben Bdira ... (+2)
  • Emna Ben Bdira
  • Maxime Kogge

BHP ltd : Q1 production update: solid in iron ore and copper but renew...

>Decent numbers in iron ore, copper and energy coal, weak in met coal and nickel - Overnight, BHP published decent, in-line production numbers for Q3 2023-24 (closed 31 March) in the core Iron Ore and Copper divisions but weak in Met Coal. Production at the main WAIO iron ore division was down 1% y-o-y at 68.1mt due to heavy rainfall, maintenance on the train network and a number of hiccups in ramping up the new mines, South Flank and Mining Area C, thus standing 1% ...

Delphine Brault ... (+2)
  • Delphine Brault
  • Quentin Borie

ABB Ltd. : A robust start to the year, part of the guidance for 2024 r...

>Q1 2024: book-to-bill of 1.14x, operational EBITA 4% above expectations - This morning, ABB published Q1 sales of $ 7,870m, up 2% l-f-l vs 5% anticipated by the consensus, an “operation EBITA” margin of 17.9% ($ 1,417m) vs 16.8% estimated ($ 1,364m) and order intake of $ 8,974m (a 4% decline l-f-l), better than expected. The book-to-bill was therefore 1.14x. By market, demand remains robust in medium-voltage but the group mentioned (for the first time) a decline in p...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch